On the onset, everything looks bad about this company except PRICE ACTION & FY23 AR (Especially Director's Report)
Some Key factors in the report
- Strategy of moving business to focussed subsidiaries has been successful - Asence Pharma has started a new Oncology and Synthetic API plant - Synbiotics is manufacturing an antifungal active ingredient - Amphotericin B - Sarabhai M Chemicals has started manufacturing Vitamin C coated products - Vovantis Labs has setup a state of art manufacturing facility to expand business - CoSara DIagnostics has the exclusive manufacturing rights in India for the complete menu of its US partner - Co-Diagnostics
So many turnaround factors which is clearly indicated by Price Action
Technicals
On a monthly chart, PA has formed a CUP and HANDLE with breakout. This is a powerful indication of confirming the fundamentals stated above.
This pick is for those who like turnaround candidates (dark horse)